<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118946</url>
  </required_header>
  <id_info>
    <org_study_id>MS.19.03.540</org_study_id>
    <nct_id>NCT04118946</nct_id>
  </id_info>
  <brief_title>Platelet Enriched Plasma for Treatment of Interstitial Cystitis</brief_title>
  <official_title>Intra Vesical Instillation Versus Submucosal Injection of Platelet Enriched Plasma for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized trial will be conducted aiming at evaluation the efficacy and safety
      of platelet enriched plasma for management of bladder pain syndrome .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with diagnosis of Interstitial cystitis/ Bladder pain syndrome</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy as measured by global response assessment &quot;GRA&quot;</measure>
    <time_frame>3 month for each case. Expected time about 18-24 months for whole study period</time_frame>
    <description>It will be measured by global response assessment as main tool. Other measurable outcomes including visual analogue scale for pain, Interstitial Cystitis Symptom Index (4 questions) and Problem Index (4 questions) (ICSI/ICPI). These measures will be collected after each session during period of administration of treatment then at 3 months after end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety : rate of complication and grade of complications graded by Dindo-Clavien classification</measure>
    <time_frame>3 month for each case. Expected time about 18-24 months for whole study period</time_frame>
    <description>patients will be asked and observed for any anticipated adverse events as hematuria, dysurea, any drug reaction. They will be kept for observation in hospital for 4 hours after delivery for treatment. Periodic reporting of any adverse event by phone call or during next visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of urinary tract infection and gynecological infection among this group</measure>
    <time_frame>3 month for each case. Expected time about 18-24 months for whole study period</time_frame>
    <description>by doing urine analysis+/- culture if indicated. By doing vaginal swap for culture if indicated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Bladder Pain Syndrome</condition>
  <condition>Platelet Enriched Plasma</condition>
  <arm_group>
    <arm_group_label>intravesical instillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravesical instillation of platelet enriched plasma every week for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>submucosal injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>submucosal injectionof platelet enriched plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet enriched plasma</intervention_name>
    <description>PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.</description>
    <arm_group_label>intravesical instillation</arm_group_label>
    <arm_group_label>submucosal injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of interstitial cystitis/ Bladder painful Syndrome for more
             than 3 months will be enrolled

        Exclusion Criteria:

          -  Patients with Anemia, blood disorders, history of pelvic irradiation, pelvic
             malignancy, and active urinary tract infection unless treated, vesical stone,
             gynecological disorders e.g. uterine fibroid and neurological disorders will be
             excluded. Patients less than 18 years old will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed El Hefnawy, Msc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor of urology .Mansoura Urology and Nephrology Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed S El Hefnawy, MD</last_name>
    <phone>01224285870</phone>
    <email>a_s_elhefnawy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Attia</last_name>
    <phone>00201090988587</phone>
    <email>drmohamedattya4@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahmed S EL Hefnawy</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed El Hefnay, MD</last_name>
      <phone>00201224285870</phone>
      <email>a_s_elhefnawy@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohammed Attya</last_name>
      <phone>00201090988587</phone>
      <email>drmohamedattya4@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nasr El TAbey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Abd El razik, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Sobhy Elhefnawy</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

